国产精品久久久久久永久牛牛,55国产福利在线视频,成人午夜精品视频在线观看

目錄產品 » 穩定細胞系 » Human Recombinant Corticotropin Releasing Factor Receptor CRF1 Stable Cell Line
CHO-K1/CRF1/Gα15 Stable Cell Line

Figure 1. CRH-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/CRF1/Gα15 cells. The cells were loaded with Calcium-4 prior to being stimulated with agonist CRH. The intracellular calcium change was normalized and measured by FLIPR. The relative fluorescent units (RFU) were normalized and plotted against the log of the cumulative doses of CRH (Mean ± SEM, n = 3). The EC50 of CRH on this cell was 13.19 nM.

Notes:
EC50 value is calculated with four parameter logistic equation:
Y=Bottom + (Top-Bottom) / (1+10^((LogEC50-X)*Hill Slope))
X is the logarithm of concentration. Y is the response
Y is % stimulation of RFU and starts at Bottom and goes to Top with a sigmoid shape.

CHO-K1/CRF1/Gα15 Stable Cell Line

Figure 2. Dose dependent stimulation of intracellular cAMP accumulation upon treatment with urocortin in CHO-K1/CRF1/Gα15 cells. d2 acceptor fluorophore -labeled cAMP (Cat. No. 62AM4PEC; Revvity) and intracellular cAMP in CHO-K1/CRF1/Gα15 cells competitively bind with Europium Cryptate-labeled anti-cAMP monoclonal antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Pherastar, BMG). The EC50 of urocortin on CHO-K1/CRF1/Gα15 cells was 0.14 nM.

CHO-K1/CRF1/Gα15 Stable Cell Line

Recombinant CHO-K1 cells stably overexpress human corticotropin releasing hormone receptor 1 (CRF1) on the surface and contain high levels of G protein Gαs to couple with the receptor in downstream signaling pathways.
M00343
詢價

聯系我們
Product Description Recombinant CHO-K1 cells stably overexpress human corticotropin releasing hormone receptor 1 (CRF1) on the surface and contain high levels of G protein Gαs to couple with the receptor in downstream signaling pathways.
Culture Properties Adherent
Stability Stable through more than 16 passages with no significant changes in assay performance or expression profile.
Size Two vials of frozen cells (>1×106 per vial in 1 mL)
Storage Store cells in liquid nitrogen immediately upon receipt. Thaw and recover cells within one year from the date received.

Culture Medium Ham’s F-12K (Kaighn’s), 10% FBS, 400 μg/ml Geneticin (Cat. No. 10131-035, Life Technologies), 100 μg/ml Hygromycin B (Cat. No. 10687010, Invitrogen)
Complete Growth Medium Ham’s F-12K (Kaighn’s), 10% FBS
Freeze Medium-DATA 45% Ham’s F-12K (Kaighn’s) (Cat. No. 21127, Life Technologies), 45% FBS (Cat. No. 10099-141, Gibco), 10% DMSO (Cat. No. D2650, Sigma)

  • CHO-K1/CRF1/Gα15 Stable Cell Line
  • CHO-K1/CRF1/Gα15 Stable Cell Line

    Figure 1. CRH-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/CRF1/Gα15 cells. The cells were loaded with Calcium-4 prior to being stimulated with agonist CRH. The intracellular calcium change was normalized and measured by FLIPR. The relative fluorescent units (RFU) were normalized and plotted against the log of the cumulative doses of CRH (Mean ± SEM, n = 3). The EC50 of CRH on this cell was 13.19 nM.

    Notes:
    EC50 value is calculated with four parameter logistic equation:
    Y=Bottom + (Top-Bottom) / (1+10^((LogEC50-X)*Hill Slope))
    X is the logarithm of concentration. Y is the response
    Y is % stimulation of RFU and starts at Bottom and goes to Top with a sigmoid shape.

  • CHO-K1/CRF1/Gα15 Stable Cell Line
  • CHO-K1/CRF1/Gα15 Stable Cell Line

    Figure 2. Dose dependent stimulation of intracellular cAMP accumulation upon treatment with urocortin in CHO-K1/CRF1/Gα15 cells. d2 acceptor fluorophore -labeled cAMP (Cat. No. 62AM4PEC; Revvity) and intracellular cAMP in CHO-K1/CRF1/Gα15 cells competitively bind with Europium Cryptate-labeled anti-cAMP monoclonal antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Pherastar, BMG). The EC50 of urocortin on CHO-K1/CRF1/Gα15 cells was 0.14 nM.


For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.


喜歡新升級的網站嗎?

討厭

不喜歡

一般

喜歡

非常喜歡

*
    主站蜘蛛池模板: 永善县| 井陉县| 宁阳县| 深水埗区| 嘉定区| 深水埗区| 马尔康县| 大连市| 尤溪县| 临洮县| 上杭县| 竹北市| 凤翔县| 淮安市| 临湘市| 阜城县| 壶关县| 乐清市| 石景山区| 贵定县| 怀宁县| 达日县| 宁强县| 原平市| 方城县| 巫山县| 广西| 道孚县| 商都县| 新安县| 江山市| 定南县| 沙河市| 镇赉县| 朔州市| 安岳县| 天台县| 晴隆县| 中阳县| 阿拉善右旗| 清新县|